Bausch + Lomb and Novaliq Report the NDA Submission of NOV03 (perfluorohexyloctane) to the US FDA for Dry Eye Disease Associated with Meibomian Gland Dysfunction
Shots:
- Bausch + Lomb and Novaliq have submitted the NDA to the US FDA seeking approval for NOV03 to treat signs and symptoms of DED associated with MGD
- If NOV03 is approved by the US FDA, it will be the first available therapy to address the signs and symptoms of this patient population. With the completion of a multi-center, open-label, single-arm, 12mos. (KALAHARI) safety extension trial, the clinical program for NOV03 came to an end
- NOV03 is an investigational, water-free, single-component preservative-free eye drop. Additionally, Bausch + Lomb got an exclusive license to develop & commercialize NOV03 in the US and Canada
Ref: PRNewswire | Image: Bausch + Lomb
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
